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Background: Experimental analysis of the metastatic cascade requires suitable model systems which allow tracing
of disseminated tumor cells and the identification of factors leading to metastatic outgrowth in distant organs.
Such models, especially models using immune-competent mice, are rather scarce. We here analyze tumor cell
dissemination and metastasis in an immune-competent transplantable mouse mammary tumor model, based on
the SV40 transgenic WAP-T mouse mammary carcinoma model.
Methods: We orthotopically transplanted into immune-competent WAP-T mice two tumor cell lines (H8N8,
moderately metastatic, and G-2, non-metastatic), developed from primary WAP-T tumors. G-2 and H8N8 cells
exhibit stem cell characteristics, form homeostatic, heterotypic tumor cell systems in vitro, and closely mimic
endogenous primary tumors after orthotopic transplantation into syngeneic, immune-competent WAP-T mice.
Tumor cell transgene-specific PCR allows monitoring of tumor cell dissemination into distinct organs, and
immunohistochemistry for SV40 T-antigen tracing of single disseminated tumor cells (DTC).
Results: While only H8N8 cell-derived tumors developed metastases, tumors induced with both cell lines disseminated
into a variety of organs with similar efficiency and similar organ distribution. H8N8 metastases arose only in lungs,
indicating that organ-specific metastatic outgrowth depends on the ability of DTC to re-establish a tumor cell system
rather than on invasion per se. Resection of small tumors (0.5 cm3) prevented metastasis of H8N8-derived tumors,
most likely due to the rather short half-life of DTC, and thus to shorter exposure of the mice to DTC. In experimental
metastasis by tail vein injection, G-2 and H8N8 cells both were able to form lung metastases with similar efficiency.
However, after injection of sorted “mesenchymal” and “epithelial” G-2 cell subpopulations, only the “epithelial”
subpopulation formed lung metastases.
Conclusions: We demonstrate the utility of our mouse model to analyze factors influencing tumor cell dissemination
and metastasis. We suggest that the different metastatic capacity of G-2 and H8N8 cells is due to their different degrees
of epithelial-mesenchymal plasticity (EMP), and thus the ability of the respective disseminated cells to revert from a
“mesenchymal” to an “epithelial” differentiation state.
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Breast cancer is one of the most common cancers
among women in developed countries, and about 16.7
percent of breast cancer patients die from the disease
due to development of metastases [1]. Outgrowth of me-
tastases may occur as late as 20 years after diagnosis and
treatment, although several studies in mouse models
suggest that cancer cell dissemination, the initial step of
metastasis, can be a very early event in the disease [2-4].
In patients, the screening for and detection of circulating
tumor cells (CTC) in blood samples and disseminated
tumor cells (DTC) in bone marrow aspirates has become
a valuable prognostic factor in patient care [5-9].
Understanding tumor cell dissemination in detail, and
analyzing the fate of CTC and DTC up to the outgrowth
of metastasis is an important task not only for further
understanding subsequent steps of the metastatic cas-
cade, but also for improving the diagnostic value of CTC
and DTC for patients [10]. As experimental studies are
very limited in humans, animal models are indispens-
able. So far, most studies are performed with xenograft
models [11,12] which, however, face the problem that
the influence of the immune system on various aspects
of metastasis cannot be analyzed. Furthermore, and des-
pite some similarities, the cellular environment of hu-
man and mouse cells may differ in important aspects.
However, suitable immune competent mouse models to
follow up metastasis formation from CTC and DTC are
scarce.
In this study we analyzed tumor cell dissemination and
metastasis in the WAP-T mouse model, a well character-
ized immune-competent mouse model for oncogene-
induced mammary carcinogenesis. WAP-T mice [13,14]
develop spontaneous mammary carcinomas upon induc-
tion via mating. Whey acidic protein (WAP) promoter
dependent expression of SV40 T antigens leads to trans-
formation of mammary epithelial cells and ultimately to
tumor growth. Additional expression of mutant p53 in bi-
transgenic WAP-T/WAP-mutp53 mice aggravates tumor
progression, and enhances metastasis to the lungs [14].
The clinical relevance of the WAP-T mouse model is em-
phasized by comparison with human ductal carcinoma in
situ [13,15] and molecular similarities between WAP-T
and human triple-negative, basal-like and non-basal-like
mammary carcinoma subtypes [16].
We succeeded in developing a WAP-T tumor cell line
(G-2 cells), which reflects tumor cell heterogeneity and
molecular characteristics of human breast carcinomas
in vitro and in vivo after orthotopic transplantation into
syngeneic WAP-T mice [17]. Due to an integrated, HA-
tagged mutp53 gene in G-2 cells, the transplantable
WAP-T-G-2 tumor cell system allows analysis of tumor
cell dissemination by a PCR assay [18]. As G-2 cell
transplanted WAP-T mice so far failed to metastasize,we developed another WAP-T tumor cell line (H8N8
cells) with similar characteristics as G-2 cells, but with
moderate metastatic capacity. We here describe the dis-
tribution and kinetics of tumor cell dissemination and of
parameters influencing metastasis formation from DTC
in WAP-T-NP8 mice transplanted with G-2 and H8N8
cells, respectively.Methods
Animals
Mice were kept, bred, and handled under SPF conditions
in the animal facility of the Heinrich-Pette-Institute as de-
scribed previously [14,17] and approved by Hamburg’s
Authority for Health (TVG 88/06, 34/08, 114/10, and 48/
12). Orthotopic tumor cell transplantation was performed
as described previously [17].Size of the animal cohorts used in this study
– evaluation of metastasis rate in primary WAP-T
tumors: BALB/c: n = 39, T1: n = 86, NP8: n = 175;
T1-H22: n = 28; NP8-H8: n = 40; NP8-W1: n = 32
and NP8-W10: n = 60.
– tumor growth kinetics of transplanted G-2 and H8N8
cells: NP8: n = 24.
– detection of DTC/CTC in transplanted NP8 mice:
n = 23
– detection of DTC/CTC in resected NP8 mice: n = 37
– immune system involvement for DTC/CTC frequency
in transplanted mice: NP8: n = 16, NSG: n = 27
– experimental metastasis: serial dilution: NP8: n = 48
– experimental metastasis: time course: NP8: n = 12
Except for the experiments involving endogenous
tumor growth, all experiments were performed with at
least two replicates.Cell culture
The WAP-T cell lines G-2 and H8N8 were cultured in
DMEM medium (PAA) supplemented with 10% FCS
(PAA) at 37°C and 5% CO2.
TGF-beta1 treatment: cells were treated 12 hours after
seeding with 5 ng/ml TGF-beta1 (solubilized in 2 mg/ml
BSA in PBS) purchased by R&D (#240-B-002/CF). Cells
were harvested after 72 h incubation for further analysis.Histology
For histological analysis, lung specimen were processed
as previously described [17]. Immunehistological stain-
ings were performed with an home-made anti SV40 T-
Ag rabbit polyclonal antibody (R15) [19] or a rabbit
polyclonal anti HA-Tag (MBL-561).
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Immunofluorescence staining was performed as described
previously [17], see Additional file 1: Table S1. Secondary
antibodies used for immunofluorescence staining were
DyLight® or Alexa®Dye conjugates obtained from Invitro-
gen or Dianova.
DNA extraction and PCR
DNA was extracted from blood and bone marrow after
lysis of erythrocytes and from snap frozen tissues after
homogenization with FastPrep by Phenol-Chloroform.
For PCR analysis 200 ng of DNA was amplified with
primers specific for the HA tag in the mutp53 expres-
sion cassette (forward GACCGCCGTACAGAAGAA-
GAA, reverse TCAGATCTTCAGGCGTAGTCG) using
the 5′-Prime Taq-DNA polymerase kit. DNA extracted
from cell lines or Balb/c mouse liver was used as con-
trols. PCRs for the mouse Notch4 gene were run in par-
allel (forward CTGCACCTAGCTGCCAGATTC and
reverse CTGTCTGCTGGCCAATAGGAG).
qPCR
RNA was purified using the Innuprep RNA-Extraction
Kit (Analytik Jena) and reverse transcribed with the High
Capacity RT kit (Applied Biosystems). PCR was per-
formed using the Power SYBR Green PCR Mastermix
(Applied Biosystems) in a standard program running in
an ABI 7500 Fast thermal cycler (Applied Biosystems).
PCR reactions for each sample were run in triplicate.
See Additional file 1: Table S1 for the list of primers.
Hspa8 was used as housekeeping gene for sample
normalization. Relative expression values for each gene
were obtained through calculation of 2–ΔΔCT values,
where ΔΔCT = delta delta CT values. Expression values
of the mock samples were used as calibrator. Delta CT
values were used for statistical analysis (Student’s t-test).
Statistical analysis
All statistical analyzes were made with Graphpad Prism
5.0.
Results
The transplantable WAP-T mammary tumor model
Mice, cell lines, and properties of transplanted tumors.
Mono-transgenic BALB/c WAP-T mice (lines WAP-T1,
short T1; WAP-T-NP8, short NP8, [13]) and bi-transgenic
Balb/c WAP-T x WAP-mutp53 mice (lines WAP-T1 x
WAP-H22, short T1-H22; WAP-NP8 x WAP-W1, short
NP8-W1; WAP-NP8 x WAP-W10, short NP8-W10 and
WAP-NP8 x WAP-H8, short NP8-H8) develop invasive
mammary carcinomas with roughly the same kinetics
within 5–8 months, but differ significantly in their
metastatic potential (Additional file 2: Figure S1A)
[14,15]). To study metastatic processes in WAP-Ttumors, we established clonal cell lines from a bi-
transgenic T1-H22 tumor (G-2 cells and derivatives;
[17]). G-2 cells, their clonal derivatives, and their
properties in forming a self-reproducing mammary
cancer cell system, have been described in detail
[15,17]. Despite their origin from a bi-transgenic T1-
H22 tumor, G-2 cells only weakly express mutp53 in
cell culture as well as in transplanted tumors [15]. We
so far did not observe metastasis when G-2 cells were
orthotopically transplanted into WAP-T mice.
We failed to establish similar cell lines from NP8-W1
and NP8-W10 mice. Similarly, it was not possible to es-
tablish such cell lines from 64 mono-transgenic T1 or
NP8 tumors. For reasons unknown to us, it was only pos-
sible to develop G-2 like mammary carcinoma cell lines
from bi-transgenic tumors containing the mutp53R270H
mutation (3 cell lines established out of 24 primary tu-
mors), e.g. H8N8 cells established from a tumor of a bi-
transgenic NP8-H8 mouse. H8N8 cells in culture show
very similar properties as G-2 cells, but strongly express
mutp53. Orthotopic transplantation of as few as 10 H8N8
cells also leads to mammary tumors of epithelial pheno-
type that show a much stronger and wider distribution
of mutp53 expression than transplanted G-2 tumors
(characterization of H8N8 in vitro as well as in vivo in
supplemental data Additional file 3: Figure S2 and data
not shown). G-2 cells transplanted NP8 mice showed an
earlier onset of growth and a slightly faster tumor growth
leading to a mean life time shortening of 14 days com-
pared to mice transplanted with H8N8 cells (Figure 1).
H8N8 tumors metastasized with a frequency of about 20%
(Additional file 2: Figure S1B), while G-2 tumors failed to
metastasize.
DTC detection in transplanted NP8 mice
Tumors and DTC of transplanted G-2 or H8N8 cells
can be discriminated from non-tumor tissue of recipient
NP8 mice by expression of SV40 T-Ag. Screening lungs
of G-2 / H8N8 tumor bearing mice for the occurrence
of metastases, occasional single T-Ag positive cells could
be found (Figure 2A). For the analysis of tumor cell dis-
semination to different organs we established a genomic
DNA based PCR which detects the specific HA-tag of
the mutp53 expression cassette in G-2 and H8N8 cell
lines (for details see [15,18]). We determined the specifi-
city of detection in BALB/c liver tissue to be in the range
of 25 tumor cells in 1.000.000 tissue cells. To exclude
the possibility that PCR detects free floating DNA we
tested serum probes of several tumor-bearing animals
for HA-DNA, and always obtained negative results (data
not shown).
To estimate the distribution of DTC in various organs,
we prepared genomic DNA from mammary gland #2
(MG#2), mammary gland #7 (MG#7), liver, spleen, lung,
Figure 1 Growth kinetics of WAP-T cell lines in NP8 recipient mice. Tumor growth kinetics (A) and latency until sacrifice (B) in G-2 (n = 13)
and H8N8 (n = 11) transplanted NP8 recipient mice. Female NP8 mice were orthotopically transplanted with 103 G-2 or H8N8 cells into mammary
gland #3 (abdominal left) and tumor growth was measured using a caliper twice per week. The median time for the growth of a 2 cm3 big tumor
was 28 days and 42 days for G-2 and H8N8 cells, respectively (log-rank test p < 0.001).
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left femur of 11 NP8 mice transplanted with H8N8 cells
and 12 NP8 mice transplanted with G-2 cells at the time
of sacrifice with a tumor volume of approx. 2 cm3. We
found DTC by PCR in every tissue with an average of 2–
3 positive tissues per mouse. However, various tissues
were not affected significantly different, as DTC were
only slightly more often found in mammary glands,
lungs and brain (Figure 2B). We did not detect HA-PCR
signals in blood and left bone marrow of mice trans-
planted with H8N8 cells and no signals in liver of mice
transplanted with G-2 cells. Altogether we conclude that
neither G-2 nor H8N8 cells display a clear organ prefer-
ence during dissemination. This was not necessarily to
be expected as metastasis of primary WAP-T tumors in
all our mouse lines is basically restricted to the lungs.
Metastasis of disseminated tumor cells
Despite significant tumor cell dissemination into various
organs from both, G-2 cell or H8N8 cell derived tumors,
metastasis rates of the transplanted tumors were quite
different for G-2 tumors (0%) compared to H8N8 tu-
mors (~20%). We first asked whether this might reflect
that G-2 cells are generally unable to colonize a target
organ once they have entered the circulation, andperformed experimental metastasis by intravenous (i.v.)
injection of 105 G-2 or H8N8 cells into the tail vein
(TV) of NP8 mice. Tumor growth in the lungs occurred
reproducibly for both cell lines. We lowered the num-
bers of TV injected cells down to 100, but did not find a
significant difference between G-2 and H8N8 cells re-
garding the amount of cells needed in the circulation to
initiate the development of lung metastases. It is esti-
mated that a tumor of 1 cm3 sheds about 106 tumor
cells per day into the circulation [20]. Thus a 0.5 cm3 G-
2 or H8N8 tumor would shed approximately 105 cells
per day. This should exclude that the quantity of tumor
cells in the circulations limits metastasis of G-2 and
H8N8 transplanted mice. As G-2 as well as H8N8 cells
are able to colonize a target tissue with similar efficiency,
and as DTC from their respective transplanted tumors
are present in sufficient numbers, we assumed that the
limited potential of DTC derived from G-2 tumors to
form metastases has other reasons.
Tumor cell dissemination and metastasis after tumor
resection
Metastasis in breast cancer often is a rather late event in
disease progression, occurring even 10 – 15 years after
successful removal of the primary tumor. We, therefore
Figure 2 Detection of DTCs in transplanted NP8 mice. (A) Representative examples of serial lung tissue sections of mice carrying G-2 tumors
at the time of sacrifice (tumor size 2 cm3), stained for T-Ag expression (red). Single positive cells (arrows) can be found in blood vessels and lung
tissue. Scale bar = 200 μm. (B) Tumor cell dissemination in G-2 and H8N8 transplanted mice. NP8 mice were orthotopically transplanted with 103
H8N8 cells (n = 11) or with G-2 cells (n = 12). Different mouse tissues, blood and bone marrow (BM) were analyzed by PCR for the occurrence of
DTC (HA-signal) at the time of sacrifice (tumor size of 2 cm3). Plotted is the percentage of mice with positive signals in the respective tissue, blood or
bone marrow. (C) Tumor cell dissemination in G-2 and H8N8 cell transplanted mice after tumor resection. NP8 mice were orthotopically transplanted
with either 103 H8N8 or G-2 cells. Tumor growth was monitored by caliper measuring. At 0.5 cm3 tumors were surgically removed and were sacrificed
at 2 months (G-2: n = 5, H8N8: n = 5) and 1 week post surgery (G-2: n = 5, H8N8: n = 4). Animals with relapse (G-2: n = 6, H8N8: n = 3) and control mice
(G-2: n = 3, H8N8: n = 6) were sacrificed at 0.5 cm3 tumor size. Different mouse tissues (mammary gland #7, liver, spleen, lung, brain), blood and bone
marrow were analyzed by PCR for the occurrence of DTC (HA-signal). Plotted is the percentage of mice with positive signals in any of the analyzed
tissues. Mice suffering a relapse of tumor growth are plotted separately.
Maenz et al. BMC Cancer  (2015) 15:178 Page 5 of 10reasoned that the lack of metastasis seen in G-2 trans-
planted mice, and the moderate metastasis rate observed
in H8N8 transplanted mice might reflect the relatively
short time of exposure to DTC. Mice after transplant-
ation with G-2 cells only live approximately 28 days be-
fore they need to be sacrificed due to tumor burden. In
contrast, mice transplanted with H8N8 cells display an
extended life span of 42 days before tumors reach 2 cm3
(Figure 1A and B). In particular, endogenous primary tu-
mors of WAP-T/WAP-mutp53 mice presumably have
much more time for establishment and outgrowth of
metastases (about 200 days after trangene induction for
NP8, NP8-W1 and NP8-W10 mice), as early tumor cell
dissemination is a well known phenomenon [2,3].
Mimicking the clinical situation we resected trans-
planted G-2 and H8N8 tumors when they reached a
palpable size (0.5 cm3, at approx. 20 days for G-2transplanted and approx. 30 days for H8N8 transplanted
tumors) and analyzed dissemination and metastasis at
different time points thereafter (1 week, 2 months). Con-
trol animals were sacrificed at a tumor size of 0.5 cm3.
At this time point, on average 70% of G-2 cell and 100%
of H8N8 cell transplanted mice presented with HA-tag-
positive tissues (Figure 2C). Tumor resection in our ex-
perimental system led to a drop in DTC frequency below
detection limit already one week post-surgery (the first
time point analyzed) and from then on. DTC frequency
went back to pre-surgery levels in animals that suffered
a relapse. We did not observe metastases in G-2 and
H8N8 transplanted mice where tumors were successfully
resected. Single transplanted mice were left alive up to
8 months post-surgery without development of metasta-
ses or relapse. We conclude that levels of disseminated
G-2 and H8N8 cells are maintained by continuous cell
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disseminated G-2 and H8N8 cells cannot survive and
proliferate in their target tissues. Mice thus are exposed
to detectable levels of DTC only during tumor growth.
The short half-life of DTC in our system explains, why
no metastases were found in H8N8 transplanted mice,
when the tumors were resected at a tumor size of
0.5 cm3, whereas about 20% of H8N8 cell transplanted
tumors metastasized when the tumors were allowed to
grow up to a volume of 2 cm3. We conclude that meta-
static outgrowth of H8N8 DTC is a rare stochastic event,
whose probability is enhanced the longer the animals are
exposed to DTC. It was not possible to test, whether
longer exposure of G-2 cell transplanted NP8 mice to
DTC would lead to metastasis, as mice have to be sacri-
ficed at a maximal tumor volume of 2 cm3 due to ethical
reasons. Furthermore, alternate parameters that limit
metastasis in G-2 transplanted mice should be consid-
ered, like immunological elimination or apoptosis of cir-
culating cells before they reach the target organ, or a
poor ability to colonize the respective target organ.
Fate of G-2 cells in experimental metastasis
We next used TV injected G-2 cells as a model for dis-
seminated G-2 cells to have a closer look at their fate
after inoculation into the circulation. Mouse lungs wereFigure 3 Experimental metastasis and influence of the immune syste
with 105 G-2 cells and sacrificed at 1 h, 1 d, 1 week and 2 weeks post injec
injection: cells have left the circulation and entered lung tissue, 20× magni
2 weeks post injection, 10× magnification. Scale bars = 100 μm (E) Tumor c
orthotopically transplanted with either 103 H8N8 or G-2 cells (H8N8 in NP8
Mice were sacrificed at a tumor volume of 2 cm3 and different mouse orga
mammary gland #2, #7, liver, spleen, lung, brain, blood, bone marrow left a
DTC and in NSG mice 5 out of 9. Statistical analysis: unpaired t test. ** p = 0prepared 1 h, 1 day, 1 week and 2 weeks after initiation
of experimental metastasis with 105 G-2 cells. Lungs
were paraffin-embedded and serial sections stained for
SV40 T-Ag by immunohistochemistry (Figure 3A-3D).
1 h after TV injection between 2 to 12 single G-2 cells
were visible in lung tissue on each analyzed section. In
parallel, we performed HA-tag-specific PCRs on differ-
ent tissues of the same mice (mammary glands 2, 3, 7,
liver, spleen, lung and blood) (Additional file 2: Figure
S1C). 1 h post injection the bulk of the signal was found
in the lungs only. One mouse showed a weak signal in
the spleen and another a very weak signal in mammary
gland #2. Assuming an equal distribution of tumor cells
within the lung, we calculated that 1 h after injection
about a quarter of the TV injected G-2 cells could be de-
tected by immunohistochemistry in the lungs. Besides in-
tact tumor cells, we already at this time point found
tumor cell debris in the lung. Remarkably, no tumor cells
or tumor cell debris were seen in blood vessels (Figure 4A).
On day 1 after TV injection we found a major drop in
SV40 T-Ag positive cells in lung tissue. Most sections did
not contain any tumor cells anymore, but each mouse har-
bored one or two sections out of 6 analyzed with a single
tumor cell. These cells were still detectable by HA-specific
PCR, though the signals were weaker. Already 1 week post
TV injection 2 out of 3 mice harbored several micro-m. Fate of TV injected tumor cells. Lung sections of mice, TV injected
tion, stained for T-Ag expression (red; arrows). (A) and (B) 1 h post
fication; (C) micrometastasis 1 week post injection; (D) metastasis
ell dissemination in immune deficient mice. NP8 and NSG mice were
n = 4, H8N8 in NSG n = 13, G-2 in NP8 n = 12 and G-2 in NSG n = 14).
ns were analyzed by PCR for the occurrence of DTC (HA-tag signal):
nd right. In NP8 mice on average 2 out of 9 tissues were positive for
.0019, *** p < 0.0001.
Figure 4 TGFß1 induced epithelial-mesenchymal plasticity (EMP) in G-2 cells. G-2 cells were treated with TGFβ1 (7.5 ng/ml) for 72 h. Relative
quantitation of (A) EMT signature gene expression and (B) epithelial and mesenchymal markers expression was performed via RT-qPCR in mock-
and TGFβ1-treated cells (n = 3 replicates). Hspa8 was used as a housekeeping gene for sample normalization. Relative expression values for each
gene were obtained through calculation of 2–ΔΔCT values, where ΔΔCT = delta delta CT values. Expression values of the mock samples were used
as calibrator. Delta CT values were used for statistical analysis (Student’s t-test). (C) Phase contrast images of either mock- or TGFβ1-treated G-2
cells. The white arrows show dense colonies of epithelial cells in untreated G-2 cell cultures; scale bar: 150 μm.
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gle T-Ag positive cells were no longer visible. 2 weeks post
TV injection, 1 out of 3 mice showed micro- and metasta-
sis in every lung section. Thus half the mice injected with
105 G-2 cells developed metastases within 1–2 weeks.
We conclude that circulating G-2 cells leave the blood
circulation within the first hour after injection to invade
adjacent tissue. Thereafter, the majority of cells fails to
proliferate and cells are eliminated. Injected with the
same amount of cells, some mice develop several lung
tumors, whereas other mice obviously are able to clear
G-2 cells. Only rarely a few dormant cells survive for
longer periods of time. Such rare dormant cells were
also occasionally observed in G-2 and H8N8 trans-
planted mice that did not develop tumors up to 6 months
post transplantation (data not shown).
Influence of the immune system on tumor cell
dissemination and metastasis
In order to find out if an immune reaction might impair
tumor cell dissemination and metastasis, we transplanted
G-2 and H8N8 cells into immune-competent NP8, and
into immune-deficient NOD scid gamma (NSG) mice. Pri-
mary tumor growth did not significantly differ between
NP8 and NSG mice. However, tumor cell dissemination
was significantly stronger in NSG mice for both, H8N8
and G-2 cell transplanted mice, with an average of 5 PCR-
positive tissues out of 9 tissues analyzed (Figure 3E)compared to NP8 mice (approx. 2 of 9 tissues analyzed).
Interestingly, the rate of metastasis of H8N8 cells in NSG
mice increased to 40% (5 out of 13 mice, Additional file 2:
Figure S1B), while no metastasis could be found in NSG
mice transplanted with G-2 cells. We conclude that in
immune-competent mice primary tumor growth is not af-
fected by the immune system, whereas a so far undefined
immune reaction corroborates the extent of tumor cell
dissemination. In the case of H8N8 tumors, the absence
of a functional immune system led to enhanced metasta-
sis, possibly corresponding to enhanced tumor cell dis-
semination. In contrast, no influence of the immune
system and of enhanced tumor cell dissemination could
be observed on metastasis of G-2 cell transplanted mice.
We conclude that disseminated G-2 cells must lack an in-
trinsic property necessary to allow colonization of a re-
spective target organ.
Epithelial-mesenchymal plasticity (EMP) is possibly the
decisive feature for metastatic outgrowth of disseminated
WAP-T tumor cells
The EMP phenotype is independent from the morphological
tumor cell phenotype
The ability of tumor cells to reversibly undergo epithelial
to mesenchymal transition (EMT) and the reverse differ-
entiation process MET (mesenchymal-epithelial transi-
tion) has been termed epithelial-mesenchymal plasticity
(EMP) [21,22], and is an important feature of metastatic
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profiles of WAP-T/WAP-mutp53 bi-transgenic tumors
and of NP8 tumors, and identified a mutp53-induced
‘EMT gene signature’ [15]. Despite an enhanced expres-
sion of genes associated with the oncogenic EMT gene
network in bi-transgenic tumors, mono- and bi-transgenic
tumors showed an indistinguishable histology, indicating
phenotypic plasticity, i.e. an EMP-phenotype of WAP-T
tumors cells.
To get further experimental support for this assump-
tion, we analyzed the phenotypic conversion of G-2 cells
in culture after application of the well-known EMT-
inducer TGFß1 [23]. TGFß1 also is a major factor of the
tumor microenvironment in WAP-T tumors [15]. As ex-
pected, a 3 day TGFß1 treatment induced a change in
cell morphology (Figure 4C), as G-2 cells almost com-
pletely lost their epithelial cell compartment, which is
typically organized in dense colonies (white arrows,
Figure 4C). Instead, treated G-2 cells now all displayed a
more homogenous, elongated, spindle-like morphology
which is characteristic for cells that have undergone EMT.
Furthermore, we tested the cells for the expression of
EMT signature genes and for the expression of phenotypic
epithelial and mesenchymal markers. 9 out of the 14 genes
of the ‘EMT gene signature’ were significantly regulated
(Figure 4A). However, concerning the expression of
phenotypic epithelial and mesenchymal markers, we ob-
served only regulation of N-cadherin, while expression
levels of EpCAM, E-cadherin and vimentin did not change
significantly (Figure 4B). Thus treatment of G-2 cells with
the potent EMT-inducer TGFβ1 induced an enhanced
plasticity of the tumor cells rather than a complete EMT,
as evidenced by the absence of changes in the levels of
phenotypic markers.
This led us to propose that the ability of DTC to
colonize a target organ most likely is more dependent
on their EMP properties than on their morphological
phenotype. EMP properties are required to quickly re-
verse from a ‘quasi-mesenchymal’ to a quasi-epithelial’
phenotype once DTC enter a target organ.
Experimental metastasis of EpCAM-sorted G-2 cells
G-2 cells, like H8N8 cells were able to efficiently
colonize the lungs in experimental metastasis after TV
injection. In these experiments cells derived from cell
culture were injected. In culture, these cells comprise a
homeostatic mixture of ‘quasi-mesenchymal’ and ‘quasi-
epithelial’ cells, i.e. of cells in states differing in their de-
gree of EMP [17]. We thus considered the possibility
that these two cell compartments might differ in their
metastatic capacity, and performed experimental metasta-
sis with FACS pre-sorted G-2 cells. 5 × 104 EpCAMhigh,
5 × 104 EpCAMlow and 5 × 104 EpCAMhigh/low mixed cells
were TV injected into NP8 mice and metastasis of thelungs analyzed after 6 weeks. 2 out of 9 mice injected with
G-2-EpCAMhigh cells, and 2 out of 9 mice injected with
G-2-EpCAMhigh/low mixed cells, but none of the 8 mice
injected with G-2-EpCAMlow cells developed metastasis.
Thus G-2 cells expressing the epithelial differentiation
marker EpCAM were more successful in establishing me-
tastasis than cells of a more mesenchymal differentiation
state. A possible explanation of this result could be that
only G-2 cells in the EpCAMhigh population are in an
EMP-state that allows colonization of the lungs.
Discussion
In this study we used two tumor cell lines, G-2 and
H8N8, to study tumor cell dissemination and metastasis
from tumors arising in immune-competent syngeneic
NP8 mice. G-2 and H8N8 cells exhibit very similar prop-
erties in cell culture and form tumors with high histological
and molecular similarity to endogenous undifferentiated tu-
mors [17,24]. As these tumors could be cross-species vali-
dated with corresponding triple-negative human tumors
[16,24], the transplantable WAP-T tumor model constitutes
a valuable tool for analyzing various aspects of tumor me-
tastasis. Both cell lines were developed from bi-transgenic
WAP-T/WAP-mutp53 tumors carrying a mutp53 mini-
gene with the R270H mutation (corresponding to the
human (R273H) mutation. Why in the WAP-T system
only mutp53R270H acted as survival factor for in vitro
culture of tumor cells is a not understood, but interesting
phenomenon. However, a pro-survival function in vitro by
inhibiting apoptosis has been described for several mutp53
proteins, including mutp53R273H [25,26]. Such a pro-
survival function of mutp53R270H might confer a growth
advantage to primary tumor cells in culture, thereby facili-
tating their establishment as a cell line.
While we so far failed to observe metastasis from G-2
transplanted NP8 mice, H8N8 mice metastasize with a
moderate frequency of about 20%. It is interesting that
expression of the transgenic mutp53R270H in G-2 cells is
rather weak and confined to single cells, while expres-
sion of mutp53R270H in H8N8 cells is strong, both
in vitro and in tumors. Whether this is only a corollary,
or is causative, remains to be investigated.
Despite the difference in metastatic capacity, tumor
cell dissemination was rather similar from tumors aris-
ing from both cell lines, and affected a variety of organs.
This was somewhat unexpected, as the vast majority of
metastases observed from endogenous tumors are found
in the lung. This implies, that organ tropism of metasta-
sis, at least in the WAP-T tumor system, is not decided
at the level of tumor cell dissemination, but rather at the
level of organ colonization.
To get clues for the different metastatic capacity of
disseminated H8N8 and G-2 cells, respectively, we first
excluded that G-2 cells are generally unable to colonize
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TV injection of G-2 and H8N8 cells into NP8 mice. Sur-
prisingly, even very low numbers of TV injected G-2 as
well as of H8N8 cells were able to form tumors in the
lungs, indicating that under this experimental setting cells
from both lines are able to leave the circulation and build
up metastases in a target organ with similar efficiency.
In analogy to the human situation, where metastasis is
a rather late event in disease progression, we resected
the transplanted tumors at a rather small tumor volume
to provide a longer time of exposure to DTC for the de-
velopment of metastases. Neither H8N8, nor G-2 cell
transplanted mice developed metastases, and mice, from
which tumors had been successfully removed, were
cured. This finding might be important for assigning the
metastatic capacity of tumors in tumor models relating
to the human situation [27]. Parallel analysis for the
presence of DTC in tumor resected mice revealed that
DTC no longer could be detected already one week after
tumor resection (the earliest time point analyzed). The
lack of metastases in H8N8 cell tumor resected mice in-
dicates that metastatic outgrowth of a disseminated
H8N8 cell is a rather rare event, which requires the con-
tinuous presence of the short-lived DTC over a longer
period of time. Experimental metastasis allowed analysis
of the fate of G-2 cells once they reach the blood circu-
lation. Interestingly, inoculated G-2 cells left the circula-
tion within the first hour, and about a quarter of the
cells reached the lungs as target organ. In accordance
with our tumor resection data, most of the cells were
eliminated rather fast, and only few cells survived and
were able to build up a metastatic lesion.
We also compared tumor cell dissemination and me-
tastasis from G-2 and H8N8 transplanted tumors in
NP8 and in NSG mice. Transplanted NSG mice showed
a significantly higher rate of tumor cell dissemination. In
the case of H8N8 cells this led to a higher rate of metas-
tasis, in accordance with our interpretation that en-
hanced or prolonged exposure of mice to disseminated
H8N8 cells enhanced the probability for metastatic out-
growth. The reason for the enhanced dissemination in
NSG mice is not known to us and its elucidation would
require more detailed analyses.
To resolve the apparent discrepancy between meta-
static efficiency of G-2 cells in experimental and in’real’
metastasis, we followed up on our recent data showing
that EMP is a decisive factor for metastasis of WAP-T
tumor cells [15]. Although G-2 cells do not lack EMP
properties, as shown by treatment of G-2 cells in culture
with TGFß1, only the EpCAMhigh and the mixed popula-
tion were able to form metastases after TV injection, when
cultured G-2 cells were separated into an EpCAMhigh and
an EpCAMlow population. There is evidence that efficient
metastasis requires re-differentiation (MET) [28,29]. Whilecells featuring EMT characteristics are by far more prone
to disseminate from the primary tumor [30,31], epithelial
cell characteristics are associated with a dramatic increase
in colonization of the secondary site [28]. We previously
showed that in vitro cells of the EpCAMlow G-2 population
are in a mesenchymal differentiation state which does not
allow a rapid conversion to the epithelial phenotype. [17].
Such conversion, however, is required for successfully
building up a viable cancer cell system in the target organ.
In contrast, the differentiation state of EpCAMhigh cells
seems to facilitate such conversion. With regard to the in-
ability of disseminated G-2 cells to metastasize, this would
imply that they are in a differentiation state which resem-
bles that of the EpCAMlow G-2 population in culture.
Conclusions
The present results have potential clinical implications.
Large-scale meta-analyses have shown that the presence
of DTCs is associated with an increased risk of relapse
and shorter survival [32]. However, many patients with
DTCs do not experience relapse within 10 years after, in-
dicating that only a subset of DTC may have the ability
to outgrow into an overt metastasis [32]. To further
understand which DTC subset is metastatic, it will be
necessary to identify the factors contributing to meta-
static outgrowth. The transplantable G-2/H8N8 WAP-T
tumor cell system described here might help to elucidate
some of the requirements necessary for a DTC to suc-
cessfully undergo the last steps in metastasis – the sur-
vival and proliferation in the target organ for metastasis.
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